Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02320214 · ClinicalTrials.gov registry record · NA

A Single-Center, Clinical Study to Evaluate the Safety of a Fragranced Personal Lubricant in Healthy Female Subjects

A NA study of Edema and Erythema, sponsored by Church & Dwight Company.

Completed
Registry status
NA
Development phase
30
Enrollment target
1
Study location

NCT02320214 is a NA study of Edema and Erythema that has completed, run by Church & Dwight Company. The registered enrollment target is 30 participants, below the 463-participant average among 13 other Edema trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02320214, a NA study of Edema and Erythema, has completed, sponsored by Church & Dwight Company.

COMPLETED
Registry status
NA
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

To evaluate the safety of Miami w/ frag Personal lubricant when used as indicated as a personal lubricant in the vagina and vulvar/perineal areas at least four times weekly for two weeks in a population of healthy females.

Conditions Studied

Interventions

  • DEVICE Miami w/ frag Personal lubricant

Study Locations (1)

New Jersey

  • Clinical Research Laboratories - Piscataway

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2014-12
Est. Completion 2015-01
Phase NA

Sponsor

Church & Dwight Company

19 total trials

What the Registry Record Tells You About NCT02320214

The ClinicalTrials.gov registry entry for NCT02320214 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 463-participant average among 13 other Edema trials with a reported enrollment target (94% lower). The listed sponsor is Church & Dwight Company, which has 19 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Edema appearing as the primary indexed condition, and to 1 intervention - of which Miami w/ frag Personal lubricant is the first listed.

NCT02320214 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.

Frequently Asked Questions

What is clinical trial NCT02320214 about?

NCT02320214 is a clinical study titled "A Single-Center, Clinical Study to Evaluate the Safety of a Fragranced Personal Lubricant in Healthy Female Subjects". To evaluate the safety of Miami w/ frag Personal lubricant when used as indicated as a personal lubricant in the vagina and vulvar/perineal areas at least four times weekly for two weeks in a population of healthy females.

What is the current status of trial NCT02320214?

This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2014-12. Estimated completion is 2015-01.

What conditions does trial NCT02320214 study?

This clinical trial studies the following conditions: Edema, Erythema.

What interventions are being tested in trial NCT02320214?

The interventions under investigation include: Miami w/ frag Personal lubricant (DEVICE).

Who is sponsoring clinical trial NCT02320214?

This trial is sponsored by Church & Dwight Company, which has 19 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02320214 being conducted?

This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Edema

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.